Correlates of high HDL cholesterol among women with coronary heart disease

被引:15
作者
Bittner, V
Simon, JA
Fong, J
Blumenthal, RS
Newby, K
Stefanick, ML
机构
[1] Univ Alabama, Div Cardiovasc Dis, Birmingham, AL 35294 USA
[2] Univ Calif San Francisco, San Francisco, CA 94143 USA
[3] Johns Hopkins Med Inst, Baltimore, MD 21205 USA
[4] Duke Univ, Durham, NC USA
[5] Stanford Univ, Palo Alto, CA 94304 USA
关键词
D O I
10.1067/mhj.2000.101224
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background The National Cholesterol Education Program (NCEP) has designated high-density lipoprotein cholesterol (HDLC) greater than or equal to 60 mg/dl a "negative" coronary heart disease (CHD) risk factor, but a substantial proportion of coronary events occur among women despite high HDL-C levels. Methods and Results The objective of this study was to characterize postmenopausal women with prevalent CHD despite HDL-C greater than or equal to 60 mg/dl and to identify factors that may attenuate the protective effect of high HDL-C. We analyzed baseline data from a randomized, double-blind study of estrogen/progestin replacement therapy in 2763 postmenopausal women <80 years old with CHD. Demographics, CHD risk factors, medications, anthropometrics, and lipid levels were compared among women with low, normal, and high HDLC by NCEP criteria with and without stratification by use of lipid-lowering medications. Independent correlates of high HDL-C were determined by logistic regression analysis. HDL-C greater than or equal to 60 mg/dl was present in 20% of participants. Women with high HDL-C were older, better educated, had fewer CHD risk factors, lower triglyceride levels and total cholesterol/HDL-C ratio, and were more likely to report past estrogen and current calcium antagonist, niacin, and statin use. beta-Blocker, diuretic, and fibrate use was less common. Older age, alcohol consumption, niacin, and calcium antagonist use and prior estrogen use were independently associated with high HDL-C, whereas waist-to-hip ratio, smoking, triglyceride level, and beta-blocker and fibrate use were inversely associated (all P < .05). Conclusions High HDL-C, as defined by the NCEP, occurred in 20% of women with CHD in this cohort without a concomitantly higher prevalence of other CHD risk factors. Redefinition of "high" HDL-C levels for women may be warranted.
引用
收藏
页码:288 / 296
页数:9
相关论文
共 34 条
[1]  
AGMON J, 1992, CIRCULATION, V86, P839
[2]   POSTMENOPAUSAL ESTROGEN AND PREVENTION BIAS [J].
BARRETTCONNOR, E .
ANNALS OF INTERNAL MEDICINE, 1991, 115 (06) :455-456
[3]   PROPRANOLOL-INDUCED LIPID CHANGES AND THEIR PROGNOSTIC-SIGNIFICANCE AFTER A MYOCARDIAL-INFARCTION - THE BETA-BLOCKER HEART-ATTACK TRIAL EXPERIENCE [J].
BYINGTON, RP ;
WORTHY, J ;
CRAVEN, T ;
FURBERG, CD .
AMERICAN JOURNAL OF CARDIOLOGY, 1990, 65 (20) :1287-1291
[4]   HDL CHOLESTEROL AND OTHER LIPIDS IN CORONARY HEART-DISEASE - COOPERATIVE LIPOPROTEIN PHENOTYPING STUDY [J].
CASTELLI, WP ;
DOYLE, JT ;
GORDON, T ;
HAMES, CG ;
HJORTLAND, MC ;
HULLEY, SB ;
KAGAN, A ;
ZUKEL, WJ .
CIRCULATION, 1977, 55 (05) :767-772
[5]   CORRELATES OF HIGH-DENSITY LIPOPROTEIN CHOLESTEROL IN WOMEN STUDIED BY THE METHOD OF CO-TWIN CONTROL [J].
COHN, BA ;
BRAND, RJ ;
HULLEY, SB .
AMERICAN JOURNAL OF EPIDEMIOLOGY, 1989, 129 (05) :988-999
[6]   HDL CHOLESTEROL PREDICTS CORONARY HEART-DISEASE MORTALITY IN OLDER PERSONS [J].
CORTI, MC ;
GURALNIK, JM ;
SALIVE, ME ;
HARRIS, T ;
FIELD, TS ;
WALLACE, RB ;
BERKMAN, LF ;
SEEMAN, TE ;
GLYNN, RJ ;
HENNEKENS, CH ;
HAVLIK, RJ .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1995, 274 (07) :539-544
[7]   REVERSE CHOLESTEROL TRANSPORT - PHYSIOLOGY AND PHARMACOLOGY [J].
FRANCESCHINI, G ;
MADERNA, P ;
SIRTORI, CR .
ATHEROSCLEROSIS, 1991, 88 (2-3) :99-107
[8]   EDUCATION, RACE, AND HIGH-DENSITY-LIPOPROTEIN CHOLESTEROL AMONG UNITED-STATES ADULTS [J].
FREEDMAN, DS ;
STROGATZ, DS ;
WILLIAMSON, DF ;
AUBERT, RE .
AMERICAN JOURNAL OF PUBLIC HEALTH, 1992, 82 (07) :999-1006
[9]   RISK-FACTORS AND THE ANATOMIC DISTRIBUTION OF CORONARY-ARTERY DISEASE [J].
FREEDMAN, DS ;
GRUCHOW, HW ;
JACOBSEN, SJ ;
ANDERSON, AJ ;
KING, JF ;
BARBORIAK, JJ .
ATHEROSCLEROSIS, 1989, 75 (2-3) :227-236
[10]  
FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499